查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
瀰漫大B细胞淋巴瘤市场：全球及区域分析与预测（2025-2035）
市场调查报告书
商品编码
1753875

瀰漫大B细胞淋巴瘤市场：全球及区域分析与预测（2025-2035）

Diffuse Large B-cell Lymphoma Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

瀰漫大 B 细胞淋巴瘤 (DLBCL) 市场的主要驱动力之一是标靶治疗的进步，尤其是 CAR-T 细胞疗法和双特异性抗体等免疫疗法。

这些治疗方法正在彻底改变復发或难治性瀰漫大B细胞淋巴瘤的治疗，提供前所未有的高效个人化治疗方案。 CAR-T细胞疗法，例如Yescarta和Kymriah，在传统化疗无效的患者中，已取得显着成功，实现了长期缓解，显着改善了患者的预后和生存期。

随着人们对免疫疗法潜力的认识不断提高，以及基因检测和生物标记分析技术的进步，人们越来越需要根据患者肿瘤的个别特征来客製化更精准的治疗方案。这些进展不仅有助于提高存活率，也减少了与传统化疗相关的副作用，而这些正是进一步推动瀰漫大B细胞淋巴瘤 (DLBCL) 市场发展的关键因素。

此外，非何杰金氏淋巴瘤(NHL) 的发生率不断上升，尤其是在老年人口中，这导致对先进治疗方案的需求日益增长。随着诊断工具的改进，更多患者能够在早期得到诊断，瀰漫大B细胞淋巴瘤 (DLBCL) 的治疗市场正在迅速扩张，这为製药公司开发和商业化创新治疗方法创造了机会。

儘管瀰漫大B细胞淋巴瘤（DLBCL）市场正在成长，但仍存在一些挑战阻碍其充分发挥潜力。其中一项主要挑战是治疗费用高昂，尤其是CAR-T细胞疗法和双特异性抗体等先进治疗方法，这些疗法通常价格昂贵，并非所有患者都能负担得起，尤其是在中低收入国家。这些治疗的高昂费用给医疗保健系统带来了沉重的负担，并限制了患者获得最具创新性的治疗方法。

另一个挑战是抗治疗性和復发。儘管CAR-T疗法和其他标靶治疗在治疗復发或难治性瀰漫大B细胞淋巴瘤方面取得了令人瞩目的成功，但仍有一些患者经历治疗失败或疾病復发。这凸显了持续创新和开发能够克服抗药性并提供更持久疗效的新治疗方法的必要性。

此外，CAR-T疗法相关的副作用，例如细胞激素释放症候群 (CRS) 和神经毒性，也令人担忧。虽然这些副作用可以透过适当的监控和护理来控制，但它们需要专门的医疗基础设施，可能会阻碍其广泛应用，尤其是在医疗条件较差的环境中。

延迟诊断仍然是一个持续的挑战：许多瀰漫性大B细胞淋巴瘤 (DLBCL) 病例确诊时已是晚期，限制了治疗效果。许多症状与其他侵袭性较低的疾病重迭，导致干预延误，而早期发现仍然是一个重大障碍。

最后，基于分子分析和遗传标记的个人化治疗的复杂性是一个挑战：虽然精准医疗具有巨大的潜力，但检测可用性和对肿瘤异质性缺乏了解等问题使得难以始终为正确的患者匹配正确的治疗。

本报告研究了全球瀰漫大 B 细胞淋巴瘤 (DLBCL) 市场，并总结了主要趋势、市场影响因素分析、法律制度、临床试验分析、市场规模趋势和预测、各个细分市场的详细分析、地区/主要国家、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球瀰漫大B细胞淋巴瘤市场：产业展望

  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 全球瀰漫大B细胞淋巴瘤市场（按地区）

  • 北美洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 欧洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

3. 全球瀰漫大B细胞淋巴瘤市场：竞争格局与公司概况

  • 关键策略和发展
    • M&A
    • 协同效应活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • AbbVie Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
    • Denovo Biopharma, Inc.
    • Calithera Biosciences, Inc.
    • Biogen Inc.
    • Autolus Therapeutics plc
    • Allogene Therapeutics, Inc.
    • Novartis AG
    • Miltenyi Biomedicine GmbH
    • Regeneron Pharmaceuticals, Inc.
    • Debiopharm International SA
    • Seagen Inc.
    • Takeda Pharmaceutical Company Limited

第四章调查方法

Product Code: BHL3035SA

Global Diffuse Large B-cell Lymphoma Market, Analysis and Forecast: 2025-2035

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive and most common form of non-Hodgkin lymphoma (NHL), a cancer that originates in the lymphatic system, which is part of the body's immune system. Diffuse Large B-cell Lymphoma is characterized by the rapid and uncontrolled growth of large B-cells, a type of white blood cell that plays a key role in immune response by producing antibodies. These abnormal B-cells grow in a diffuse pattern, meaning they spread throughout the affected tissue, often involving lymph nodes, spleen, bone marrow, and other organs.

Diffuse Large B-cell Lymphoma typically presents as a fast-growing tumor, and the symptoms can vary depending on the area affected, but common symptoms include swollen lymph nodes, fever, night sweats, unexplained weight loss, and fatigue. If untreated, Diffuse Large B-cell Lymphoma can rapidly progress and affect vital organs, which can lead to organ failure.

Diffuse Large B-cell Lymphoma is most diagnosed in adults, particularly those over the age of 60, but it can also occur in younger individuals. Diagnosis is typically confirmed through biopsy of the affected lymph node or tissue, followed by immunohistochemistry and genetic tests to assess the characteristics of the lymphoma cells.

The treatment for diffuse Large B-cell Lymphoma typically includes chemotherapy (such as R-CHOP, which combines Rituximab with chemotherapy drugs) and immunotherapy. In cases where the disease is resistant to treatment or recurs, CAR-T cell therapy and bispecific antibodies are emerging as effective options.

With prompt diagnosis and treatment, many patients with Diffuse Large B-cell Lymphoma can achieve remission, but the disease remains aggressive, and early intervention is crucial for improving survival outcomes.

One of the key drivers of the Diffuse Large B-cell Lymphoma (DLBCL) market is the advancement in targeted therapies, particularly immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are revolutionizing the treatment of relapsed or refractory diffuse Large B-cell Lymphoma, offering highly effective and personalized treatment options that were previously unavailable. CAR-T cell therapies such as Yescarta and Kymriah have shown remarkable success in achieving long-term remission in patients who have failed conventional chemotherapy, significantly improving patient outcomes and survival rates.

The growing recognition of immunotherapy's potential, combined with advancements in genetic testing and biomarker profiling, is driving the demand for more precise treatment options tailored to the individual characteristics of patients' tumors. These advancements are not only improving survival rates but also reducing the side effects associated with traditional chemotherapy, which remains a critical factor in driving the Diffuse Large B-cell Lymphoma market forward.

Furthermore, the increasing prevalence of non-Hodgkin lymphoma (NHL), especially in the aging population, is contributing to the rising demand for advanced treatment options. As more patients are diagnosed at earlier stages due to improved diagnostic tools, the Diffuse Large B-cell Lymphoma market for Diffuse Large B-cell Lymphoma therapies is expanding rapidly, creating opportunities for pharmaceutical companies to develop and commercialize innovative treatments.

Despite the growth of the Diffuse Large B-cell Lymphoma (DLBCL) market, several challenges continue to impede its full potential. One of the primary challenges in Diffuse Large B-cell Lymphoma market is the high cost of treatment, particularly with advanced therapies like CAR-T cell therapy and bispecific antibodies, which are often expensive and may not be accessible to all patients, especially in low- and middle-income countries. The cost of these therapies places a significant burden on healthcare systems and limits patient access to the most innovative treatment options.

Another challenge is treatment resistance and relapse. While CAR-T therapies and other targeted treatments have shown impressive results in treating relapsed or refractory Diffuse Large B-cell Lymphoma, a subset of patients still experience treatment failure or disease recurrence. This highlights the need for continuous innovation and the development of additional therapies that can overcome resistance and provide more durable responses.

Additionally, side effects from treatments, including cytokine release syndrome (CRS) and neurological toxicities associated with CAR-T therapies, remain a concern. Although these side effects are manageable with proper monitoring and care, they require specialized healthcare infrastructure, which can be a barrier to widespread adoption, especially in less-equipped healthcare settings.

Late diagnosis is another ongoing issue, as many Diffuse Large B-cell Lymphoma cases are diagnosed at advanced stages, limiting the effectiveness of treatment. Early detection remains a significant hurdle, as many of the symptoms overlap with other, less aggressive conditions, delaying intervention.

Finally, the complexity of personalized treatment based on molecular profiling and genetic markers presents challenges. While precision medicine offers significant potential, there are issues related to the availability of testing and the understanding of tumor heterogeneity, making it difficult to always match the right treatment to the right patient.

Diffuse Large B-cell Lymphoma market challenges highlight the need for continued innovation, affordable access, and better healthcare infrastructure to fully realize the potential of Diffuse Large B-cell Lymphoma treatments and improve patient outcomes.

The global Diffuse Large B-cell Lymphoma (DLBCL) market is highly competitive, with several key players driving innovation and market growth. Leading companies such as AbbVie Inc. (Genmab A/S), Merck KGaA, F. Hoffmann-La Roche AG, and Johnson & Johnson (Janssen Pharmaceuticals, Inc.) are at the forefront, developing cutting-edge therapies to address the unmet needs of Diffuse Large B-cell Lymphoma patients. These companies are focusing on novel treatment approaches like CAR-T cell therapies, bispecific antibodies, and monoclonal antibodies that are showing significant promise in improving patient outcomes, particularly in relapsed or refractory cases. Additionally, companies like Biogen Inc., Novartis AG, and Regeneron Pharmaceuticals, Inc. are investing heavily in immunotherapies and targeted treatments, which are reshaping the treatment landscape and expanding the scope for long-term remission and improved survival rates. The ongoing research and strategic partnerships within these companies are driving continued advancements in the Diffuse Large B-cell Lymphoma market, contributing to a growing demand for more personalized, effective, and less toxic treatment options. As the Diffuse Large B-cell Lymphoma market continues to evolve, these leaders remain integral in providing innovative therapies for better management of Diffuse Large B-cell Lymphoma.

Diffuse Large B-cell Lymphoma Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Diffuse Large B-cell Lymphoma (DLBCL) market is experiencing several key emerging trends that are reshaping the landscape of diagnosis, treatment, and patient care. One of the most significant trends in Diffuse Large B-cell Lymphoma market is the increasing focus on immunotherapy, particularly CAR-T cell therapy and bispecific antibodies. These therapies represent a shift towards targeted and personalized treatments, offering improved efficacy in relapsed or refractory Diffuse Large B-cell Lymphoma cases where traditional chemotherapy has often failed. CAR-T therapies, such as Yescarta and Kymriah, are showing promising results in inducing long-term remissions and are becoming an integral part of the Diffuse Large B-cell Lymphoma treatment landscape.

Another emerging trend is the growing emphasis on combination therapies, where immunotherapy is used in conjunction with chemotherapy or other targeted therapies. This approach aims to enhance treatment effectiveness by addressing multiple pathways that contribute to disease progression. Bispecific antibodies like epcoritamab, which target both CD3 on T-cells and CD20 on B-cells, are gaining momentum due to their ability to more effectively engage the immune system and directly target lymphoma cells.

Additionally, the focus on personalized medicine is reshaping the treatment approach for Diffuse Large B-cell Lymphoma. Advances in genetic profiling and biomarker testing are allowing clinicians to better understand the molecular characteristics of individual patients' tumors, enabling the selection of therapies tailored to the specific needs of the patient. This trend towards precision medicine is leading to more effective and less toxic treatments, improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Diffuse Large B-cell Lymphoma Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Diffuse Large B-cell Lymphoma Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Diffuse Large B-cell Lymphoma Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Diffuse Large B-cell Lymphoma Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Diffuse Large B-cell Lymphoma Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Diffuse Large B-cell Lymphoma Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 AbbVie Inc.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Merck KGaA
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 F. Hoffmann-La Roche AG
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Denovo Biopharma, Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Calithera Biosciences, Inc.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Biogen Inc.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Autolus Therapeutics plc
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Allogene Therapeutics, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Novartis AG
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Miltenyi Biomedicine GmbH
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Regeneron Pharmaceuticals, Inc.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Debiopharm International SA
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Seagen Inc.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Takeda Pharmaceutical Company Limited
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Diffuse Large B-cell Lymphoma Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Diffuse Large B-cell Lymphoma Market Key Trends, Analysis

List of Tables

  • Table: Global Diffuse Large B-cell Lymphoma Market Dynamics, Impact Analysis
  • Table: Global Diffuse Large B-cell Lymphoma Market (by Region), $Billion, 2024-2035